Bluejay Diagnostics (NASDAQ:BJDX) Posts Quarterly Earnings Results

Bluejay Diagnostics (NASDAQ:BJDX) announced its earnings results on Thursday. The company reported ($1.95) EPS for the quarter, Zacks reports.

Bluejay Diagnostics Price Performance

NASDAQ:BJDX traded down $0.06 on Friday, reaching $1.77. 8,119 shares of the company’s stock were exchanged, compared to its average volume of 17,898. The firm has a market cap of $1.82 million, a price-to-earnings ratio of 0.00 and a beta of 0.72. Bluejay Diagnostics has a 52 week low of $1.65 and a 52 week high of $16.68. The stock has a fifty day simple moving average of $1.93 and a 200-day simple moving average of $3.58.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bluejay Diagnostics has an average rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.